These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35937947)

  • 21. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
    Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
    Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
    Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
    Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Zhou J; Zuo M; Li L; Li F; Ke P; Zhou Y; Xu Y; Gao X; Guan Y; Xia X; Yi X; Zhang X; Huang Y
    Front Oncol; 2022; 12():824632. PubMed ID: 35223507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
    Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.
    Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A
    Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.
    Yuan X; Yu T; Zhao J; Jiang H; Hao Y; Lei W; Liang Y; Li B; Qian W
    Front Med; 2023 Oct; 17(5):889-906. PubMed ID: 37418076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence And Clinical Significance Of Oncogenic
    Chen YP; Ke LF; Lu JP; Wang JC; Zhu WF; Chen FF; Lin SF; Xu CW; Wu MJ; Chen G
    Onco Targets Ther; 2019; 12():10165-10175. PubMed ID: 32063711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.
    Dubois S; Jardin F
    Expert Rev Hematol; 2016 Mar; 9(3):255-69. PubMed ID: 26652775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of local treatment in primary breast B-cell non-Hodgkin's lymphoma: a propensity score matching-based analysis from SEER database.
    Zhang M; Liu N; Wang BY; Zhang J; Zhao A; Yang J; Yang J
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):22-31. PubMed ID: 35049015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
    Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
    Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
    Yhim HY; Kang HJ; Choi YH; Kim SJ; Kim WS; Chae YS; Kim JS; Choi CW; Oh SY; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Lee JJ; Sung HJ; Kim HJ; Lee DH; Suh C; Kwak JY
    BMC Cancer; 2010 Jun; 10():321. PubMed ID: 20569446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.
    Zhou C; Cui Y; Sun H; Yang F; Zhao H; Huangfu L; Zhang J
    Transl Cancer Res; 2021 Jun; 10(6):2632-2642. PubMed ID: 35116576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Zhu Q; Wang J; Zhang W; Zhu W; Wu Z; Chen Y; Chen M; Zheng L; Tang J; Zhang S; Wang D; Wang X; Chen G
    Front Genet; 2022; 13():878618. PubMed ID: 35646048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.